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Abstract 
Objective: Prior studies demonstrate mitochondrial dysfunction with increased reactive oxygen species generation 
in peripheral blood mononuclear cells in diabetes mellitus. Oxidative stress‑mediated damage to mitochondrial DNA 
promotes atherosclerosis in animal models. Thus, we evaluated the relation of mitochondrial DNA damage in periph‑
eral blood mononuclear cells s with vascular function in patients with diabetes mellitus and with atherosclerotic 
cardiovascular disease.
Approach and results: We assessed non‑invasive vascular function and mitochondrial DNA damage in 275 patients 
(age 57 ± 9 years, 60 % women) with atherosclerotic cardiovascular disease alone (N = 55), diabetes mellitus alone 
(N = 74), combined atherosclerotic cardiovascular disease and diabetes mellitus (N = 48), and controls age >45 
without diabetes mellitus or atherosclerotic cardiovascular disease (N = 98). Mitochondrial DNA damage measured 
by quantitative PCR in peripheral blood mononuclear cells was higher with clinical atherosclerosis alone (0.55 ± 0.65), 
diabetes mellitus alone (0.65 ± 1.0), and combined clinical atherosclerosis and diabetes mellitus (0.89 ± 1.32) as 
compared to control subjects (0.23 ± 0.64, P < 0.0001). In multivariable models adjusting for age, sex, and relevant 
cardiovascular risk factors, clinical atherosclerosis and diabetes mellitus remained associated with higher mitochon‑
drial DNA damage levels (β = 0.14 ± 0.13, P = 0.04 and β = 0.21 ± 0.13, P = 0.002, respectively). Higher mitochon‑
drial DNA damage was associated with higher baseline pulse amplitude, a measure of arterial pulsatility, but not with 
flow‑mediated dilation or hyperemic response, measures of vasodilator function.
Conclusions: We found greater mitochondrial DNA damage in patients with diabetes mellitus and clinical athero‑
sclerosis. The association of mitochondrial DNA damage and baseline pulse amplitude may suggest a link between 
mitochondrial dysfunction and excessive small artery pulsatility with potentially adverse microvascular impact.
© 2016 Fetterman et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Type 2 diabetes mellitus affects an estimated 1 in 10 
Americans and this number is expected climb with 
the current obesity epidemic [1]. Diabetes mellitus is a 
significant risk factor for cardiovascular disease; however, 
the mechanisms behind this increased risk are incom-
pletely understood [1, 2]. Elevated oxidant levels have 
been shown to contribute to vascular dysfunction both in 
animal models and clinical studies [3–5]. Mitochondria 
are an important source and target of oxidants that may 
contribute to vascular disease in diabetes mellitus [6–8].
Mitochondrial DNA is more susceptible to oxida-
tive damage compared to nuclear DNA due to multiple 
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factors including a limited repair capacity and close 
proximity to the electron transport chain [9, 10]. Mito-
chondrial DNA damage has been closely associated with 
dysfunctional oxidative phosphorylation, which leads to 
further oxidative stress resulting in a positive-feedback 
cycle. In an animal model of atherosclerosis, excess 
mitochondrial DNA damage promoted atherosclerosis 
and plaque vulnerability through increased monocyte 
activation [11]. In a prior human study of patients with 
coronary artery disease, the extent of mitochondrial 
DNA damage in circulating white cells was associated 
with high risk plaque burden [12]. We have previously 
described altered mitochondrial oxidative phosphoryla-
tion, membrane potential and morphology in peripheral 
blood mononuclear cells which was associated with vas-
cular dysfunction in patients with diabetes [7, 13]. The 
objective of the present study was to assess the relation of 
mitochondrial DNA damage in peripheral blood mono-
nuclear cells to vascular function and the presence of dia-
betes mellitus and atherosclerotic cardiovascular disease.
Methods
Study participants
We enrolled four groups of patients (N = 275): (1) clini-
cally established atherosclerotic cardiovascular disease 
(Athero; coronary artery disease and/or peripheral artery 
disease); (2) diabetes mellitus (DM; fasting glucose levels 
>126 mg/dL or medication therapy); (3) diabetes mellitus 
and atherosclerosis (Athero + DM); (4) controls with no 
clinically established atherosclerosis, no diabetes mellitus 
(fasting glucose <100 mg/dL) and age >45 years. Patients 
with clinical atherosclerotic cardiovascular disease were 
enrolled from outpatient cardiology and vascular surgery 
practices. Coronary artery disease was defined based on 
angiography or documented history of myocardial infarc-
tion. Peripheral artery disease was defined as ankle bra-
chial index ≤0.9 or prior peripheral revascularization. All 
participants gave written informed consent and all study 
protocols were approved by the Boston Medical Center 
Institutional Review Board.
Study protocol
Clinical history and relevant clinical covariates were 
compiled from participant interviews and medical 
records. Blood pressure was assessed with an automatic 
recorder (Dinamap; General Electric Healthcare) and 
body mass index (BMI) was calculated from measured 
height and weight. All studies were performed in the 
fasted state. Peripheral blood mononuclear cells were 
isolated by differential centrifugation of a blood sample. 
Briefly, venous blood was collected into a density gradient 
solution for the isolation of lymphocytes and monocytes 
(BD Vacutainer CPT cell preparation tubes with sodium 
citrate; Becton, Dickinson, and Company) and the tubes 
were spun at 3000 rpm for 30 min at room temperature. 
Cell layers were collected, pelleted, and stored at −80 °C 
until further processing for quantitative PCR.
Vascular function testing
Conduit arterial endothelial function was assessed using 
flow-mediated vasodilation. Hyperemic flow serves as 
the stimulus for vasodilation through endothelial-derived 
nitric oxide. A Toshiba SSH-140A ultrasound system was 
used to determine brachial artery diameter at baseline 
and for 1 min following 5 min of forearm cuff occlusion 
as previously described [14]. Brachial artery diameter 
was also measured prior to and 3 min following admin-
istration of 0.4  mg sublingual nitroglycerin. Nitroglyc-
erin was not administered if the participant declined or 
had previous adverse reactions to nitroglycerin, migraine 
headaches, severe carotid stenosis, systolic blood pres-
sure <100 mmHg, or had used sildenafil, tadalafil, or var-
denafil within 1 week of their study visit. Flow-mediated 
dilation data was assessed with commercially available 
software (Brachial Analyzer version 3.2.3, Medical Imag-
ing Applications).
Peripheral arterial tonometry
Digital pulse amplitude was measured using a PAT device 
(Endo-PAT2000, Itamar Medical, Caesarea, Israel) placed 
on the tip of each index finger. Baseline pulse amplitude 
was assessed in each finger for 2  min and 20  s follow-
ing which arterial flow was interrupted for 5  min with 
a cuff placed on a proximal forearm (Hokanson AG101, 
D.E. Hokanson Inc, Bellevue Was). The PAT result is 
expressed as the natural logarithm of the ratio of the 
pulse amplitude during the 90–120  s period after cuff 
release in the test finger to the baseline amplitude divided 
by the similar ratio from the contralateral control finger 
(ln PAT ratio) [15, 16].
Mitochondrial DNA damage quantification
Quantitative PCR was used to measure mitochondrial 
DNA damage in peripheral blood mononuclear cells 
from patients as previously described [10, 17]. Total 
DNA was extracted using the QIAmp DNA mini kit 
(Qiagen, Hilden, Germany) and quantified using Pico-
green (Invitrogen, Carlsbad, CA). A large fragment of 
the mitochondrial genome was amplified (16.2  kb) and 
normalized to copy number using a short quantitative 
PCR reaction (236 bp). Using this method, the polymer-
ase remains bound to undamaged DNA and replicates a 
full length product; however in the presence of damaged 
DNA (e.g. stand breaks, cross-links, or bulky adducts), 
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the polymerase stalls and can no longer produce full 
length products resulting in a decrease in amplification. 
The lesion frequency (LF) was calculated as previously 
described and is an estimate of the average number of 
lesions per copy of mitochondrial DNA [10, 17]. Mito-
chondrial DNA copy number is the quantification of the 
236 bp short PCR product.
Statistical analyses
Clinical characteristics and vascular measures were com-
pared across the four groups (controls, atherosclerosis 
alone, diabetes mellitus alone, and atherosclerosis with 
diabetes mellitus) using one-way ANOVA or Chi squared 
testing for continuous or categorical data, respectively. 
Mitochondrial DNA damage was compared across the 
four groups using one-way ANOVA with post hoc test-
ing for intergroup comparisons. Linear regression mod-
els were used to assess the association of mitochondrial 
DNA damage with diabetes mellitus, atherosclerosis, 
and cardiovascular risk factors. We performed a multi-
variable linear regression model comparing the relation 
of mitochondrial DNA damage to diabetes mellitus and 
atherosclerosis after adjusting for cardiovascular risk fac-
tors including age, sex, race, hypertension, BMI, smoking 
ever, hypercholesterolemia, and systolic blood pressure. 
We compared mitochondrial DNA damage and vascu-
lar measures with Spearman’s correlations. In an unad-
justed model, the sample size of 275 has 80 % power to 
detect a correlation coefficient of 0.16 and 90 % power to 
detect a correlation coefficient of 0.19. Hence, the study 
has sufficient power to evaluate for a modest correla-
tion coefficient between vascular measures and clinical 
characteristics. Data are reported as mean ± SD, unless 
otherwise specified. Two-sided P < 0.05 was considered 
statistically significant. All statistical analyses were car-
ried out using IBM SPSS Statistics version 20.
Results
Study population
The clinical characteristics and vascular measures across 
the four groups are summarized in Table  1. The overall 
mean age was 57 ±  9  years with 60 % female and 38 % 
black race. Fewer women were represented in the ath-
erosclerosis (CAD and/or PAD) group than men. As 
expected, atherosclerosis alone or in the presence of dia-
betes mellitus was associated with higher burden of car-
diovascular risk factors. Additionally, the prevalence of 
cardiometabolic factors was higher in the diabetes mel-
litus alone group. Consistent with prior reports, multiple 
measures of vascular function were impaired with ath-
erosclerosis, diabetes mellitus, and atherosclerosis and 
diabetes mellitus.
Association of mitochondrial DNA damage with diabetes 
mellitus and atherosclerosis
Mitochondrial DNA damage was higher in each of the 3 
patient groups (atherosclerosis alone, diabetes mellitus 
alone, and combined atherosclerosis and diabetes melli-
tus) as compared to controls (Fig. 1). We did not observe 
any differences in mitochondrial DNA copy num-
ber between the patient groups (atherosclerosis alone, 
0.76 ±  0.73; diabetes mellitus alone, 0.76 ±  0.45; ather-
osclerosis and diabetes mellitus, 1.2 ± 1.0) compared to 
controls (1.0 ± 1.08, P = NS). As shown in Table 2, dia-
betes mellitus and atherosclerosis were associated with 
higher mitochondrial DNA damage in unadjusted mod-
els and in models adjusting for the presence of cardiovas-
cular risk factors. Additional cardiovascular risk factors 
were not associated with the extent of mitochondrial 
DNA damage. Mitochondrial DNA damage correlated 
with measures of fasting glucose (r =  0.130, P =  0.037) 
and HOMA-IR (r  =  0.155, P  =  0.02) across the entire 
study group. However, the association of mitochondrial 
DNA damage with fasting glucose (r = −0.16, P = 0.869) 
and HOMA-IR (r = 0.091, P = 0.353) was not significant 
in the subgroup of patients with diabetes mellitus sug-
gesting that the presence of diabetes is the important 
driver of the association. Mitochondrial DNA damage 
remained associated with diabetes mellitus and athero-
sclerosis in models including cardiovascular and antidia-
betic therapies (ACE inhibitor or ARB therapy, β-blocker 
therapy, lipid lowering therapy, antiplatelet therapy, 
insulin therapy, metformin therapy, or sulfonylureas) as 
potential covariates.
Comparison of mitochondrial DNA damage with measures 
of vascular function
As shown in Table 3, there was an association of higher 
mitochondrial DNA damage with higher baseline pulse 
amplitude (P = 0.009). Other measures of vascular func-
tion including baseline brachial diameter, flow-mediated 
vasodilation, nitroglycerin-mediated vasodilation, and 
PAT ratio were not associated with mitochondrial DNA 
damage. In a multivariable model adjusting for cardio-
vascular risk factors (age, sex, body-mass index, smoking, 
hypertension, and diabetes) mitochondrial DNA damage 
remained associated with higher baseline pulse ampli-
tude (β = 67 ± 31, P = 0.03).
Discussion
In this study, we evaluated mitochondrial DNA damage 
in peripheral blood mononuclear cells and related the 
findings to vascular function in a large group of patients 
with diabetes mellitus, clinical atherosclerosis, and con-
trols. We observed higher mitochondrial DNA damage 
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in peripheral blood mononuclear cells in association with 
both diabetes mellitus and clinical atherosclerotic disease 
when accounting for concomitant cardiovascular risk 
factors including age. We observed similar levels of mito-
chondrial DNA damage in patients with diabetes mellitus 
compared to established atherosclerotic disease, which 
is consistent with the concept of diabetes as a coronary 
disease equivalent. No differences in mitochondrial DNA 
copy number were observed in any of the patient groups 
relative to the controls suggesting that the differences in 
mitochondrial DNA damage were not due to alterations 
in mitochondrial DNA copy number. Mitochondrial 
DNA damage was associated with higher baseline pulse 
Table 1 Clinical characteristics
Mean ± standard deviation or percent as appropriate
Athero atherosclerosis, DM diabetes mellitus, CAD coronary artery disease, BP blood pressure, LDL low density lipoprotein, HDL high density lipoprotein, ACE 
angiotensin-converting enzyme, ARB angiotensin receptor blocker, PAT peripheral artery tonometry
* P < 0.01 by ANOVA or Chi squared as appropriate









 Age, years 55 ± 7 60 ± 10 55 ± 10 62 ± 8
 Female, % 49 18 47 31
 Black race, % 31 27 65 29
 Hypertension, % 21 67* 70* 88*
 Hypercholesterolemia, % 56 82* 61* 85*
 Smoking ever, % 47 78 58 64
 Family history of CAD, % 32 38 27 46
 Body mass index, kg/m2 27.6 ± 5.0 29.6 ± 6.0* 34.3 ± 8.4* 31.3 ± 4.9*
 Systolic BP, mmHg 123 ± 15 130 ± 20* 135 ± 18* 141 ± 20 *
 Diastolic BP, mmHg 73 ± 9 74 ± 11 76 ± 8 78 ± 27
 Total cholesterol, mg/dl 204 ± 42 168 ± 39* 176 ± 37* 150 ± 39*
 LDL cholesterol, mg/dl 124 ± 40 97 ± 31* 101 ± 29* 82 ± 32*
 HDL cholesterol, mg/dl 58 ± 22 45 ± 14* 46 ± 15* 42 ± 13*
 Triglycerides, mg/dl 112 ± 82 134 ± 76 147 ± 95* 135 ± 95
 Fasting glucose, mg/dl 92 ± 12 107 ± 27* 181 ± 85* 163 ± 73*
 Insulin, uU/ml 7.4 ± 5.6 13.3 ± 13.8* 17.7 ± 25.6* 13.2 ± 11.5*
 ACE inhibitor or ARB therapy, N (%) 8 45* 46* 54*
 β‑blocker therapy, N (%) 7 44* 23* 62*
 Lipid lowering therapy, N (%) 9 87* 42* 71*
 Antiplatelet therapy, N (%) 15 93* 44* 69*
 Insulin therapy, N (%) 0 0 43* 38*
 Metformin therapy, N (%) 0 0 53* 33*
 Sulfonylureas, N (%) 0 0 7* 8*
Vascular measures
 Baseline brachial diameter, mm 4.11 ± 0.65 4.57 ± 0.63* 4.39 ± 0.75 4.46 ± 0.64*
 Baseline brachial velocity, cm/s 16 ± 9 16 ± 6 16 ± 6 18 ± 8
 Brachial artery flow‑mediated dilation, % 9.3 ± 4.5 7.0 ± 3.9* 6.6 ± 4.3* 6.8 ± 4.0*
 Nitroglycerin‑mediated dilation, % 13.5 ± 6.1 9.2 ± 5.7* 10.4 ± 5.1 9.2 ± 6.1*
 ln baseline pulse amplitude 5.7 ± 0.88 6.4 ± 0.63* 6.0 ± 0.78 6.3 ± 0.73*
 ln PAT ratio 0.75 ± 0.37 0.56 ± 0.33* 0.64 ± 0.39 0.55 ± 0.51


















Fig. 1 Mitochondrial DNA damage was higher in in the presence of 
DM alone, athero alone, and athero + DM as compared to controls 
(*P < 0.05 vs control, †P = 0.001 vs control)
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amplitude consistent with an alteration of microvascu-
lar pulsatility. In contrast, there were no associations of 
mitochondrial DNA damage with measures of vasodila-
tor responses in either conduit or microvessels. Taken 
together, our findings provide evidence that diabetes 
mellitus and atherosclerotic cardiovascular disease are 
associated with increased mitochondrial DNA damage 
that may be relevant to oxidative stress and microvascu-
lar dysfunction.
Prior work indicates a link between mitochondrial 
alterations, diabetes mellitus and atherosclerosis. In 
previous work by our group, we found that peripheral 
blood mononuclear cells from patients with diabetes 
mellitus had an abnormal mitochondrial phenotype 
characterized by higher mitochondrial oxidant produc-
tion, mitochondrial membrane hyperpolarization, higher 
uncoupled respiration, and fragmented mitochondria [7, 
13]. In the current study, we have extended our previ-
ous work by measuring mitochondrial DNA damage in 
circulating white cells. Mitochondrial DNA damage is 
postulated as a measure of environmental injury to the 
mitochondria that may mediate mitochondrial dysfunc-
tion. The ability to measure mitochondrial DNA damage 
in circulating white cells has potential utility as a bio-
marker of mitochondrial injury. Damage to mitochon-
drial DNA has been shown to mediate mitochondrial 
dysfunction including alterations in calcium handling, 
oxidant-mediated activation of cell stress pathways, and 
metabolic disturbances [5, 11, 12, 18]. Oxidative stress 
has been shown to induce mitochondrial DNA damage 
in vascular cells (endothelial and vascular smooth mus-
cle cells) [19]. Additionally, mitochondrial DNA damage 
has been shown to be the result of replication errors and 
repair insufficiencies with the damaged mitochondrial 
DNA undergoing clonal expansion [20, 21]. Animal mod-
els with a genetic predisposition to increased mitochon-
drial DNA damage display mitochondrial dysfunction 
and accelerated atherosclerosis [11, 18]. Interestingly, 
enhanced mitochondrial DNA damage was associated 
with abnormal metabolic function including glucose 
intolerance consistent with a connection to diabetes mel-
litus [16]. Further, monocytes with increased mitochon-
drial DNA damage were pro-inflammatory and were 
associated with increased plaque vulnerability [17].
Several prior studies have measured specific mito-
chondrial DNA changes in blood cells from patients 
with atherosclerosis and diabetes mellitus. Patients with 
coronary artery disease were found to have higher levels 
of the common mitochondrial DNA 4977 bp deletion in 
circulating peripheral blood mononuclear cells com-
pared to age matched, healthy controls [22]. In a study 
of patients with coronary artery disease, higher mito-
chondrial DNA damage was associated with vulnerable 
plaque characteristics and history of diabetes mellitus 
[18]. In an additional study, peripheral blood cells from 
diabetic patients had higher levels of a specific mitochon-
drial DNA point mutation (A3243G) compared to non-
diabetic controls [23]. Using a sensitive quantitative PCR 
based technique to determine mitochondrial DNA dam-
age, we demonstrate the presence of higher mitochon-
drial DNA damage in peripheral blood mononuclear cells 
both in patients with diabetes mellitus and with clinical 
atherosclerosis [10, 17]. This method allowed us to assess 
damage throughout the mitochondrial genome rather 
than at a single nucleotide position and is sensitive to 
strand-breaks, deletions, dimers, cross-linking, and bulky 
adducts allowing us to assess a number of different types 
of damage. Our findings suggest the independent associ-
ation of both metabolic disease and atherosclerosis with 
mitochondrial DNA damage even when accounting for 
associated cardiovascular risk factors. The greater extent 
of mitochondrial DNA damage may drive increased pro-
duction of mitochondrial reactive oxygen species and 
accentuate vascular damage in diabetes mellitus. The 




β (SE) P β (SE) P
Diabetes mellitus 0.220 (0.110) <0.001 0.213 (0.127) 0.002
Atherosclerosis 0.153 (0.115) 0.01 0.140 (0.134) 0.04
Hypertension 0.107 (0.112) 0.08 −0.037 (0.137) 0.6
Hypercholesterolemia 0.136 (0.120) 0.02 0.093 (0.124) 0.1
Smoking ever 0.034 (0.115) 0.6 −0.007 (0.117) 0.9
Age, years 0.003 (0.006) 0.6 −0.030 (0.007) 0.6
Sex 0.046 (0.115) 0.4 0.023 (0.120) 0.7
Race 0.012 (0.115) 0.842 0.002 (0.124) 0.9
BMI 0.099 (0.008) 0.1 0.043 (0.009) 0.5
Table 3 Relation of  mitochondrial DNA damage and  vas-
cular function




Baseline brachial diameter, mm 0.114 0.06
Flow‑mediated dilation, % −0.026 0.7
Nitroglycerin‑mediated dilation, % −0.02 0.8
Baseline pulse amplitude, au 0.19 0.009
ln PAT ratio −0.086 0.2
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association of mitochondrial DNA damage with ath-
erosclerosis suggests that mitochondrial DNA damage 
measures in a blood sample may serve as novel biomark-
ers of cardiovascular injury. Future studies are needed 
to evaluate the predictive value of mitochondrial DNA 
damage for cardiovascular events in a longitudinal study.
Several lines of evidence indicate the relevance of mito-
chondrial phenotype to vascular function [24]. Mito-
chondrial dysfunction in the endothelium disrupts nitric 
oxide signaling and impairs vasodilation [6, 25]. Relevant 
to the present work, studies of peripheral blood mononu-
clear cells have shown an association of lower mitochon-
drial mass, higher mitochondrial superoxide production, 
and altered oxidative phosphorylation with impaired 
vascular function in diabetes mellitus [7, 13]. We now 
show that mitochondrial DNA damage relates to higher 
baseline pulse amplitude measured in the fingertip cir-
culation. Baseline pulse amplitude measures microvessel 
pulsatility and is governed by blood flow, vessel compli-
ance and sympathetic tone. Higher small vessel pulsa-
tility may lead to microcirculatory injury and has been 
associated with several cardiovascular risk factors [15, 
26]. In one prior study of high risk patients, baseline 
pulse amplitude was not associated with large vessel 
cardiovascular events; however, the predictive value for 
microcirculatory events is not known [27]. The relation 
of mitochondrial DNA damage to higher pulse amplitude 
may reflect an impact on resting sympathetic tone or 
small vessel compliance.
In contrast, we did not observe associations of mito-
chondrial DNA damage with measures conduit and 
microvascular vasodilator function. The present finding 
differs from our prior studies showing impaired flow-
mediated dilation and peripheral arterial tonometry 
hyperemic response in the presence of mitochondrial 
dysfunction. The lack of association may suggest that 
mitochondrial DNA damage is not an important media-
tor of endothelial dysfunction. It is also possible that 
mitochondrial DNA damage does not directly modu-
late mitochondrial reactive oxygen species generation 
in peripheral blood mononuclear cells. A recent study 
demonstrated that a novel regulator of kinases and phos-
phatases, prolyl-isomerase-1 (Pin1), mediates alterations 
in mitochondrial oxidant production and downstream 
vascular signaling pathways relevant to vascular tone and 
inflammation [28]. Pin1 levels were higher in the pres-
ence of diabetes and associated with impaired endothelial 
function and higher oxidative stress biomarkers, con-
sistent with a connection between mitochondrial DNA 
damage and vascular function in patients [28]. Hence, it 
remains possible that greater mitochondrial DNA dam-
age extent or injury in vascular cells would lead to vasodi-
lator dysfunction. Additional studies will be necessary to 
define whether the microvascular changes observed with 
mitochondrial DNA damage in peripheral blood mono-
nuclear cells contribute to target-organ consequences 
and the relevance of mitochondrial DNA damage in cells 
types important to vascular disease including leukocytes, 
platelets, endothelial cells, and smooth muscle cells.
Our study has a number of limitations. We assessed 
mitochondrial DNA damage in peripheral blood mono-
nuclear cells and not a vascular tissue such as endothe-
lial cells or vascular smooth muscle cells from patients. 
However, peripheral blood mononuclear cells are a read-
ily accessible cell type in human subjects and are exposed 
to the same systemic risk factors. Additionally, due to the 
study design, we are limited to identifying correlations 
of mitochondrial DNA damage with vascular function 
rather than causal relations. Some of the types of mito-
chondrial DNA damage measured using the quantitative 
PCR technique may not affect mitochondrial function. 
However, we did observe an association of mitochondrial 
DNA damage with atherosclerosis and diabetes mellitus. 
One of the reasons for a lack of association of several vas-
cular function measures with mitochondrial DNA dam-
age may be due to the global assessment of mitochondrial 
DNA damage rather than measuring damage or mutation 
of a specific site of mitochondrial DNA. Further, mito-
chondria are responsible for multiple cellular activities 
including calcium storage, apoptosis, metabolism, regu-
lation of cell growth, and heme biosynthesis. The optimal 
assessment of mitochondrial function is likely to com-
bine multiple facets including mitochondrial oxidative 
stress, mitochondrial structure, mitochondrial complex 
activity, and mitochondrial DNA damage. Future work 
will be needed to assess the relationship of the multiple 
facets of mitochondrial function with vascular measures. 
We found an association of mitochondrial DNA damage 
with the presence of clinically evident atherosclerosis; 
however, we do not have measurements of subclinical 
atherosclerosis such as carotid-intima media thickness in 
our patient sample. Finally, further studies will be needed 
to define the mechanisms linking mitochondrial DNA 
damage to risk factors and to microvascular alterations. 
Strengths include the relatively large sample size, the 
comprehensive noninvasive assessment of vascular func-
tion, and the use of established quantitative PCR based 
methodology to measure mitochondrial DNA damage.
Conclusions
Our main findings indicate an association of mitochon-
drial DNA damage in peripheral blood mononuclear 
cells with microvascular pulsatility but not vasodilator 
function. Furthermore, both diabetes mellitus and clini-
cal atherosclerotic disease associate with greater mito-
chondrial DNA damage consistent with prior work 
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showing abnormalities in mitochondrial function. Addi-
tional work is required to elucidate the contribution of 
mitochondrial phenotype in microvascular disease and 
whether therapies aimed at protecting the mitochondria 
from DNA damage will have cardiovascular benefit.
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